Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
Background. Treatment options of recurrent malignant gliomas are very limited and with a poor survival benefit. The results from phase II trials suggest that the combination of bevacizumab and irinotecan is beneficial. Patients and methods. The medical documentation of 19 adult patients with recurre...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2015-03-01
|
| Series: | Radiology and Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/raon-2014-0021 |